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In February 2012, the novel respiratory syncytial virus 
(RSV) group A, genotype ON1, was detected in Kilifi 
County, coastal Kenya. ON1 is characterized by a 72-nt 
duplication within the highly variable G gene (encoding the 
immunogenic attachment surface protein). Cases were di-
agnosed through surveillance of pneumonia in children at 
the county hospital. Analysis of epidemiologic, clinical, and 
sequence data of RSV-A viruses detected over 5 RSV sea-
sons (2010/2011 to 2014/2015) indicated the following: 1) 
replacement of previously circulating genotype GA2 ON1, 
2) an abrupt expansion in the number of ON1 variants de-
tected in the 2014/2015 epidemic, 3) recently accumula-
tion of amino acid substitutions within the ON1 duplicated 
sequence, and 4) no clear evidence of altered pathoge-
nicity relative to GA2. The study demonstrates the public 
health importance of molecular surveillance in defining the 
spread, clinical effects, and evolution of novel respiratory 
virus variants.
Respiratory syncytial virus (RSV) is a major cause of pneumonia and bronchiolitis among infants and chil-
dren globally (1,2). Although immune responses develop 
in those who have had RSV infection during childhood, 
these persons remain susceptible to RSV upper respira-
tory tract reinfection throughout life (3). No licensed 
RSV vaccine exists. Of the 11 proteins encoded by the 
RSV genome, the attachment glycoprotein (G) is the most 
variable and has been shown to accumulate amino acid 
changes over time (4). RSV is classified into 2 groups, 
RSV-A and RSV-B (5); each group is divided into geno-
types (6), and these are further characterized into variants 
(7). Globally, RSV viruses belonging to different groups, 
genotypes, and variants often co-circulate in epidemics 
(7,8). The phenomenon of reinfection and difficulty in 
developing a vaccine may in part be due to the antigenic 
diversity and variability in the virus (9).
Two novel RSV genotypes with large duplications of 
amino acids in the attachment G glycoprotein have been 
detected globally. In 1999, the BA genotype was detected 
in Buenos Aires, Argentina; the genotype had a 60-nt du-
plication within the C-terminal region of the G gene (10). 
The BA variant subsequently spread rapidly throughout the 
world, becoming the predominant group B genotype, and 
in some regions replacing all previous circulating RSV-B 
genotypes (11). More recently, in December 2010, geno-
type ON1, with a 72-nt duplication (also within the C-
terminal region of the G gene), was detected in Ontario, 
Canada (12). Viruses belonging to this genotype have rap-
idly spread and diversified globally (13–20). Such emer-
gent genotypes appear to have a fitness advantage over pre-
ceding genotypes of the same RSV group (21). Of public 
health interest is whether increased fitness is associated 
with increased severity and immune evasion (with potential 
vaccine modality implications).
The temporal progression of RSV genotypes can be 
followed directly because of the unique tags (the dupli-
cations), which provides a rare opportunity to learn more 
about the introduction, spread, severity, and related selec-
tion processes (including immune evasion) for RSV and to 
obtain insights into the nature of emergence of novel virus 
variants. In this regard, we undertook an in-depth analysis 
of RSV-A genotype ON1 epidemiology in Kilifi, a county 
in coastal Kenya. In Kilifi, RSV epidemics typically begin 
during September–November of 1 year and continue until 
July–August of the following year, with a peak in cases dur-
ing January–March. We have analyzed sequence data col-
lected over 5 RSV epidemic seasons in Kilifi (2010/2011 
to 2014/2015), which includes the period after the initial 
detection of this novel genotype within Kilifi.
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Materials and Methods
Study Location and Population
The study was undertaken in Kilifi County and is part of 
surveillance aimed at understanding the epidemiology and 
disease effects of RSV-associated pneumonia cases in this 
region (22). Respiratory swab samples (combined nasopha-
ryngeal and oropharyngeal) were collected from Septem-
ber 2010 through August 2015 from children ages 1 day 
to <5 years admitted to Kilifi County Hospital (KCH) with 
syndromically defined severe or very severe pneumonia 
(referred to here as lower respiratory tract infections, LR-
TIs), as defined in Table 1 and previously (22)
Study Samples and Laboratory Procedures
All specimens were screened for RSV by 2 methods 
(22–24). Raw samples were tested for RSV antigen by im-
munofluorescence antibody test (Chemicon International 
Inc., Temecula, CA, USA). Viral RNA was extracted from 
respiratory samples using QIAamp Viral RNA Mini Kit 
(QIAGEN, Hilden, Germany) and tested for RSV (differ-
entiating groups A and B) by multiplex real-time reverse 
transcription PCR. All RSV-positive samples by either test 
were taken forward for processing. In addition, a small 
number of RSV-negative samples were sequenced.
The viral RNA was reverse transcribed into cDNA 
by using the Omniscript RT Kit (QIAGEN). The cDNA 
was then amplified with primers targeting the G ectodo-
main region (3,25), and the amplicons were sequenced by 
using BigDye version 3.1 chemistry on an ABI 3130xl 
(Applied Biosystems, Waltham, MA, USA). Sequence 
reads were assembled into contigs by using Sequencher 
version 5.0.1 (Gene Codes Corp., Ann Arbor, MI, USA). 
The sequences analyzed here have been deposited in 
GenBank (accession nos. KX453303–KX453534); previ-
ously reported sequences from Kilifi added to this analy-
sis had also been deposited in GenBank (accession nos. 
KF587911–KF588014) (13).
Global Comparison Dataset
To determine the relatedness of the Kilifi viruses to those 
circulating around the world and thereby clarify their glob-
al context, we downloaded all RSV-A G-gene sequences 
collected during 2010–2015; deposited in GenBank as of 
January 19, 2016; and 241 nt to 687 nt in length. A total of 
995 sequences from 24 countries were used in this analysis. 
For the whole dataset and for some countries, we further 
grouped sequences by calendar year for temporal analysis. 
We subsampled unique sequences (sequences that differed 
by >1 nt from any other sequence over the sequenced re-
gion) by epidemic season (Kilifi only) or per calendar year.
Sequence Alignments and Diversity Analysis
All sequences, from Kilifi and the global dataset, were col-
lated and aligned using MAFFT (multiple alignment using 
fast Fourier transform) alignment software version 7.272 
(26). We calculated the variability of nucleotides and ami-
no acids using MEGA 6.06 (27).
Phylogenetic Analyses
We used MEGA 6.06 to infer maximum-likelihood phylo-
genetic trees under the general time reversible model with 
the site heterogeneity gamma model (27). This model was 
the best substitution model as determined by IQ-TREE 
version 1.4.2 (28). Bootstrapping with 1,000 iterations was 
implemented to evaluate branch support of the phylogenet-
ic clusters. We assigned RSV-A genotypes as previously 
determined by Peret et al. (6) and Eshaghi et al. (12). To 
position the genotype ON1 viruses in the global context, 
we examined ON1 lineages as recently assigned by Duv-
vuri et al. (20).
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Table 1. Demographic and clinical characteristics of children with 
pneumonia caused by respiratory syncytial virus A genotypes 
ON1 and GA2 who were admitted to Kilifi County Hospital, 
Kenya, September 2010–August 2015* 
Characteristic 
Genotype, no. (%) 
ON1 GA2 Total 
Age, y    
 <1 223 (85.4) 158 (87.3) 381 (86.2) 
 >1 38 (14.6) 23 (12.7) 61 (13.8) 
Sex    
 F 118 (45.2) 70 (38.6) 188 (42.5) 
 M 143 (54.8) 111 (61.3) 254 (57.5) 
Cough    
 No 5 (1.9) 4 (2.2) 9 (2.0) 
 Yes 256 (98.1) 177 (97.8) 433 (98.0) 
Breathing difficulty    
 No 15 (5.8) 3 (1.7) 18 (4.1) 
 Yes 246 (94.3) 178 (98.3) 423 (95.9) 
Chest wall indrawing    
 No 6 (2.3) 6 (3.3) 12 (2.7) 
 Yes 255 (97.7) 175 (96.7) 430 (97.3) 
Inability to feed    
 No 211 (81.2) 165 (91.2) 376 (85.3) 
 Yes 49 (18.9) 16 (8.8) 65 (14.7) 
Oxygen saturation, %    
 >90 214 (82.0) 144 (79.6) 358 (81.0) 
 <90 47 (18.0) 37 (20.4) 84 (19.0) 
Prostration/unconsciousness   
 No 240 (92.0) 172 (95) 412 (93.2) 
 Yes 21 (8.0) 9 (5.0) 30 (6.8) 
Pneumonia status    
 Severe† 203 (77.8) 137 (75.7) 340 (76.9) 
 Very severe‡ 58 (22.2) 44 (24.3) 102 (23.1) 
Hospital stay, d    
 1–4 160 (62.0) 101 (55.8) 261 (59.4) 
 >4 98 (38.0) 80 (44.2) 178 (40.5) 
Outcome    
 Survived 250 (96.9) 177 (97.8) 427 (97.3) 
 Died 8 (3.1) 4 (2.2) 12 (2.7) 
*The denominator was 442 samples but for some of the features it ranged 
from 439 to 442 
†[Cough or difficulty in breathing] and chest wall indrawing 
‡[Cough or difficulty in breathing] and hypoxic or prostrate/unconscious. 
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RSV-A Variants Analysis
We determined the number of genotype GA2 and ON1 
variants circulating in Kilifi and globally using a recently 
developed pragmatic criterion (7,8). In brief, a variant is 
a virus or a group of viruses within a genotype that pos-
sesses ≥4 nt differences in the G ectodomain region when 
compared with other viruses. This analysis was done using 
usearch v8.1.1861 (29).
Protein Substitution and Selection Analysis
The N-glycosylation sites were predicted by using the 
NetNGlyc 1.0 server (30). We only considered the default 
Asn-X-Ser/Thr sequon (when X was not proline) for pre-
diction. We also analyzed for patterns of change in amino 
acids using python scripts. Finally, we looked for potential 
positively selected and co-evolving sites using the Dat-
amonkey server (http://www.datamonkey.org/). For posi-
tive selection analysis, we used 3 methods: SLAC (single 
likelihood ancestor counting), FEL (fixed effects likeli-
hood), and MEME (mixed effects model for evolution).
Statistical Analyses
We explored associations between demographic, clinical, 
or outcome variables and RSV genotypes for all cases of 
RSV-positive severe and very severe pneumonia. We used 
logistic regression computing odds ratios (ORs) in Stata 
version 13 (StataCorp LP, College Station, TX, USA).
Results
Over the 5 RSV epidemics examined (2010/2011 to 
2014/2015), a total of 4,010 samples were collected from 
eligible children; 3,561 (88.8%) were tested for RSV and 
881 (24.7%) RSV-positive samples were identified (on-
line Technical Appendix Table 1, https://wwwnc.cdc.gov/
EID/article/23/2/16-1149-Techapp1.pdf). Of these sam-
ples, 600 (68.1%) were RSV-A. The G gene was success-
fully sequenced in 442 (73.7%) samples. An additional 41 
sequences were available from samples that were nega-
tive by both immunofluorescent antibody test and PCR or 
from patients with mild pneumonia (data for these cases 
were not included in the clinical severity analysis). Thus, 
we carried 483 sequences for phylogenetic analysis. The 
sequences ranged from 618 nt to 690 nt in length, cor-
responding to nucleotides 295–912 of the reference strain 
A2 (M74568).
We found that 2 RSV-A genotypes were circulating in 
Kilifi: ON1 (n = 283, 58.6%) and GA2 (n = 200, 41.4%). 
The temporal prevalence of the total RSV, RSV-A, and 
genotypes ON1 and GA2 is shown in Figure 1 and on-
line Technical Appendix Table 1. We observed rapid re-
placement of the previously circulating dominant GA2 
genotype by ON1 in Kilifi, from a prevalence of 0% in the 
2010/2011 epidemic to a prevalence of 67.4% in 2011/2012 
when ON1 was first detected in Kilifi, and to 96.1% in the 
recent 2014/2015 epidemic. In addition, RSV-A predomi-
nated in 3 consecutive RSV epidemics from 2012/2013 to 
2014/2015.
To investigate the demographic and clinical effects of 
RSV-A genotype ON1 in Kilifi, we compared the propor-
tions of GA2- and ON1-infected case-patients by sex, age, 
clinical features of cough, difficulty in breathing, chest wall 
indrawing, inability to drink, hypoxia, prostration/conscious-
ness, pneumonia status (severe or very severe pneumonia), 
length of hospital stay, and death at the hospital (Table 1). 
The proportions of both genotypes were very similar for the 
demographic and clinical characteristics analyzed. However, 
the proportion of patients with ON1 infection who were un-
able to eat was more than double that for GA2-infected case-
patients (18.9% vs. 8.8%), and this difference was found sig-
nificant by logistic regression (OR 2.40, 95% CI 1.31–4.36; 
Table 2). Nonetheless, the proportion with very severe pneu-
monia was no higher in ON1 infections than in GA2 infec-
tions (OR 0.89, 95% CI 0.57–1.39).
The maximum-likelhood tree shows the clustering of 
unique genotype ON1 sequences in Kilifi (Figure 2). Two 
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Figure 1. Circulating patterns of respiratory syncytial virus (RSV) 
in Kilifi, Kenya, September 2010–August 2015. A) Total RSV-
positive cases (gray continuous line) and typed RSV-A samples 
(dotted orange line) by month. B) The proportion of RSV-A 
genotypes ON1 (black) and GA2 (white) per epidemic season. 
An RSV epidemic season is designated to start in September of 
1 year until August of the following year. Unusually, for the last 3 
seasons, group A represents most of all RSV cases
Respiratory Syncytial Virus A Genotype ON1, Kenya
genotype ON1 lineages recently defined by Duvvuri et al. 
(20) are shown to be circulating in Kilifi: lineages ON1 
[1.1] and ON1 [1.3]. Of these 2 lineages, ON1 [1.3] was the 
most prevalent in 2011/2012 and 2012/2013. However, a 
potential new lineage, denoted here as ON1 [1.4], clustered 
away from ON1 [1.3] and seemed to have recently arisen 
comprising sequences from the strains circulating in the 
2013/2014 and 2014/2015 epidemics. The genetic diver-
gence (p distance) between ON1 [1.4] and the other ON1 
lineages identified in Kilifi ranged from 0.013 to 0.045, 
similar to the genetic distances between the previously de-
fined ON1 lineages.
We detected a total of 66 RSV-A variants during the 
entire surveillance period in Kilifi (online Table 3, http://
wwwnc.cdc.gov/EID/article/23/2/16-1149-T3.htm). The 
variants comprised 1–82 sequences; 39 (59.1%) of the 66 
variants were singletons. Most variants did not persist be-
tween epidemics (46/66 [69.7%]). However, 14 variants 
persisted for 2 consecutive seasons, 1 for 4 consecutive 
seasons, and 5 for 2 nonconsecutive seasons. Therefore, the 
number of variants (accumulated by epidemic) increased 
to 86 by 2014/2015. The number of GA2 variants declined 
consistently, from 17 variants in 2010/2011 (before ON1 
arrived) to only 4 variants in 2014/2015. On the other hand, 
the number of ON1 variants assigned remained at 5 vari-
ants between 2011/2012 and 2012/2013 before increasing 
to 8 variants in 2013/2014, then rising markedly to 25 vari-
ants in 2014/2015.
Seven codon sites were predicted to be N-glycosylated 
within the G protein for the Kilifi sequences: 4 sites for 
genotype ON1 viruses (codons 103, 135, 237, 318) and 6 
sites for genotype GA2 viruses (codons 103, 135, 237, 251, 
273, 294). However, none of the potential N-glycosylation 
sites occurred within the 72-nt duplication of the ON1 vi-
ruses. Notably for GA2 viruses, sites 237 and 273 were 
mutually exclusive: a virus belonging to this genotype had 
either these sites potentially N-glycosylated but not both 
(online Technical Appendix Figure 1). 
The nucleotide variability and amino acid variability 
over the 4 seasons are shown in online Technical Appen-
dix Table 2. Amino acid substitutions over the sequenced 
portion of the G protein are shown in Figure 3, panel A. 
Two codon positions possessed amino acid substitutions 
that distinguished between ON1 (232G, 253K) and GA2 
(232E, 253T) viruses. In addition, the new ON1 [1.4] lin-
eage viruses seem to have fixed a threonine (I/T136T) and 
acquired a unique substitution (P206Q) that distinguishes 
them from the other ON1 lineages.
Figure 3, panels B and C, illustrates amino acid sub-
stitutions within the duplication region of the Kilifi ON1 
viruses. We designated the first set of 72 nt as duplication 
sequence I and the second set as duplication sequence II. 
Within this region, we observed that over the 3 seasonal 
epidemics from 2011/2012 to 2013/2014 and early (Sep-
tember–November) in the 2014/2015 epidemic, amino acid 
substitutions only occurred within the duplicated sequence 
I except for 3 substitutions in 2 viruses within the dupli-
cated sequence II. Beginning in December 2014, however, 
we found numerous substitutions in duplicated sequence 
II with 2 adjacent and corresponding positions between 
the duplicated sequences I and II acquiring similar amino 
acid substitutions (i.e., Y273H and Y297H, P274L/S and 
P298L/R). Furthermore, sites 273 and 297 were detected 
to be co-evolving from the Spidermonkey analysis (http://
www.datamonkey.org/). However, only 1 ON1 codon site 
(251) was identified to be positively selected with p<0.05 
by >1 method (SLAC, FEL, or MEME).
Using global datasets for genotypes ON1 and BA, we 
compared the temporal detection of RSV variants within 
each of these genotypes during the first 5 and 10 years, 
respectively, from initial detection (online Technical Ap-
pendix Table 3). We observed an explosion of new ON1 
variants globally, from 8 variants in 2011, to 78 variants 
in 2012, to 153 variants in 2013. However, the number 
of ON1 variants decreased in 2014 and 2015, which cor-
responded with a substantial decrease in both the number 
of ON1 sequences available in GenBank and the countries 
that have deposited sequences from these years. On the 
other hand, the number of BA variants seemed to follow 
a stepwise or punctuated pattern, whereby the number of 
variants was stable at 1–6 during 1996–2001, dramatically 
increased and stabilized at 20–30 variants during 2002–
2004, and again sharply rose to 82 variants in 2005 (online 
Technical Appendix Table 3). At the country level (online 
Technical Appendix Table 4), the rapid rise in the number 
of ON1 variants detected in Kilifi was also observed in the 
Philippines and Germany, although the number of BA vari-
ants detected in some of the countries sampled remained 
relatively stable over time.
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Table 2. Clinical severity comparison between cases of 
pneumonia caused by respiratory syncytial virus A genotypes 
ON1 and GA2 in children admitted to Kilifi County Hospital, 
Kenya, September 2010–August 2015* 
Characteristic 
Unadjusted odds 
ratio (95% CI) p value 
Age <1 y 0.85 (0.49–1.49) 0.579 
Male sex 0.76 (0.52–1.12) 0.172 
Clinical features   
 Cough 1.16 (0.31–4.37) 0.830 
 Breathing difficulty 0.28 (0.08–0.97) 0.045 
 Chest wall indrawing 1.46 (0.46–4.59) 0.520 
 Inability to feed 2.40 (1.31–4.36) 0.004 
 Oxygen saturation <90% 0.86 (0.53–1.38) 0.521 
 Prostration/unconsciousness 1.67 (0.75–3.74) 0.211 
Pneumonia status, very severe 0.89 (0.57–1.39) 0.609 
Hospital stay, >4 d 0.77 (0.53–1.14) 0.192 
Outcome, died 1.416 (0.42–4.78) 0.575 
*The denominator was 442 samples but for some of the features it ranged 
from 439 to 442. 
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Discussion
We provide a detailed analysis on the spread and the as-
sociated demographic, clinical, and evolutionary character-
istics of the novel RSV-A genotype ON1 in Kilifi. ON1 
was first detected in Kilifi in February 2012, and within 
that RSV epidemic (2011/2012), it displaced the previous 
dominant genotype GA2 by attaining a prevalence of 67%. 
Its dominance has continued to rise to 96% within a span of 
4 epidemics. This rapid rate of replacement is unlike previ-
ous replacement rates in the same location; for example, 
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Figure 2. Maximum-likelihood phylogenetic tree of unique respiratory syncytial virus (RSV) genotype ON1 G gene ectodomain 
sequences from Kilifi, Kenya, 2012–2015. The taxa are color coded by the epidemic season of detection (key), and the names represent 
KEN/Kilifi/serialnodate of collection. Note that although the study detected RSV ON1 in the epidemic season 2011/2012, the first ON1 
cases were in 2012. Scale bar indicates nucleotide substitutions per site.
Respiratory Syncytial Virus A Genotype ON1, Kenya
when GA5 was displaced by GA2, it took GA2 ≈7 years 
to reach a prevalence of 95% (8). ON1 seems to possess a 
fitness advantage over GA2. If such fitness is the result of 
immune evasion, this characteristic has potential implica-
tions for vaccines to deliver population level immunity by 
herd protection (31).
We found evidence that infections caused by RSV 
ON1 are more severe than those caused by GA2, show-
ing a higher prevalence of patients’ inability to eat. How-
ever, overall numbers of cases of very severe pneumonia 
were equal for both genotypes. The data, therefore, do not 
provide a strong indication of more severe disease aris-
ing from the ON1 variant. Duvvuri et al. (20) reported 
significant association of RSV ON1 infection with female 
patients, which was not evident in our study. Yoshihara 
et al. (32) reported that cases of upper respiratory infec-
tion caused by RSV ON1 in Vietnam caused were signifi-
cantly associated with clinically severe manifestations of 
wheezing, tachypnea, and difficulty in breathing compared 
to infections caused by RSV NA1, whereas Panayiotou et 
al. (33), on the contrary, reported that children infected 
with RSV ON1 in Cyprus experienced significantly milder 
illness than those infected with RSV GA2. Some studies 
have reported no differences at all between infections with 
these genotypes. The discordant results may arise from 
methodologic differences in analyses, clinical disease defi-
nitions, and study designs, chance effects resultant from 
inadequate sample sizes, differences between viruses in 
different locations, or even host/environmental differenc-
es. Prospective studies specifically designed to evaluate 
virulence or clinical differences between genotypes may 
offer more reliable insight.
We noted a change in the alternation of RSV subgroup 
dominance pattern in Kilifi since ON1 was introduced into 
this community. While ON2 was replacing GA2, it also 
appeared to also exclude group B strains. RSV-A pre-
dominated over RSV-B in 3 consecutive epidemics from 
2012/2013 to 2014/2015. Previously, according to data col-
lected during 2002–2012 in Kilifi, RSV-A predominated in 
up to 2 consecutive epidemics (8). However, it is unclear 
whether this is a direct effect of ON1, a general change in 
RSV epidemiologic patterns, or a chance occurrence.
Globally, the prevalence of ON1 seems to vary by lo-
cation. In Ontario, Canada, where ON1 was first detected 
in December 2010, the prevalence of ON1 has remained 
stable at 11%–13% (20). Other countries that have simi-
larly reported ON1 prevalence rates <20% include South 
Africa (34) and China (35). Reports from Italy (14), South 
Korea (36), United States (17), Malaysia (37), Japan (19), 
Thailand (16), Latvia (38), and Cyprus (33) indicate var-
ied RSV ON1 prevalence of 20%–70%. A recent article 
reported that ON1 was the sole (100%) RSV-A genotype in 
Buenos Aires, Argentina, in 2014 (39). The varying preva-
lence suggests that even though ON1 is rapidly spreading 
globally, host or ecologic differences may determine RSV 
spread. However, the conclusions of host and ecological 
differences potentially driving varying prevalence rates in 
different countries may have been confounded by inade-
quate/short surveillance periods in these countries.
As shown here and in previous research from Kilifi 
(7,8), RSV epidemics are composed of multiple variants, 
each differing sufficiently to suggest separate introductions 
into the community (as opposed to arising from diversifica-
tion during the epidemic). In addition, these variants of-
ten do not persist between epidemics, which suggests that 
each year 1) variants generate local herd immunity, leading 
to their demise, thus requiring reintroductions; or 2) that 
many invading variants compete in seeding new seasonal 
epidemics, and that the preceding year variants lose out 
(perhaps on a chance basis or as stated above because they 
are less fit due to variant specific immunity).
RSV accumulates amino acid changes over time (4), 
and we have similarly observed accumulation of amino 
acid changes in the Kilifi ON1 viruses. It is of interest that 
in the first 3 RSV epidemic seasons in which we detected 
ON1 in Kilifi, amino acid substitutions were almost al-
ways restricted to the duplicated sequence I of the 72-nt 
duplication. However, in the 2014/2015 epidemic a vir-
tual explosion in amino acid substitutions was observed 
within the duplicated sequence II that coincided with a 
surge in the number of detected ON1 variants. In addition, 
similar amino acid substitutions occurred in 2 adjacent 
and corresponding sites in the duplicated sequences I and 
II, with 1 set of these sites co-evolving. The longer attach-
ment protein of the 72-nt duplication in ON1 viruses ap-
pears to offer more opportunities for variable changes and 
thus greater diversity and increased fitness over previous 
group A genotypes.
Two codon sites, 232 and 253, within the G protein 
region analyzed were found to distinguish between geno-
type ON1 and GA2 viruses. The amino acid change Glu-
232-Val has been reported for RSV-A escape mutants that 
result in loss of reactivity to a specific monoclonal anti-
body (4). Furthermore, a functional analysis of the 60-nt 
duplication in BA strains has shown that the duplicated 
region in the G protein of these viruses augment their fit-
ness (21). While a similar analysis has not been reported 
for ON1, it is plausible that the increased fitness observed 
in ON1 is largely due to the 72-nt duplication. However, 
G-protein N-glycosylation seems to play no role in the 
increased fitness of ON1 as similar potential N-glycosyl-
ation codon sites were detected in both ON1 and GA2 and 
no additional N-glycosylation sites were detected within 
the ON1 duplication region.
The rapid diversification of ON1 observed in Kilifi 
seems to reflect rapid expansion at the global level. While 
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sampling variability may play a role, and similar to vary-
ing prevalence, there was variability in the diversification 
of ON1 viruses in different countries. The number of ON1 
variants seemed stable in some countries (e.g., Japan) while 
expanding in others (e.g., Germany and Philippines). The 
temporal distribution of BA variants in different countries, 
however, was mostly stable. Comparisons in the temporal 
patterns of genotypes BA and ON1 variants may highlight 
differences between the RSV group B and A viruses. In-
creased sampling and surveillance will help illuminate on 
whether such inter-genotypic and RSV group differences 
are due to ecologic differences or variable sampling.
In conclusion, it is evident that genotype ON1 is not 
only rapidly spreading globally but also fast evolving. The 
result is the near exclusion of the previous dominant group A 
GA2 genotype. The implications of this apparent increased 
fitness of RSV-ON1 have yet to be resolved. There is some 
evidence for increased severity of the virus but this is by 
no means clear or consistent across studies. Continued sur-
veillance for cases together with collection of detailed stan-
dardized clinical data are warranted. The possibility exists 
that ON1 and other similar new RSV variants (e.g., the BA 
genotype) gain dominance by evading host immunity. It is 
reasonable to assume this could lead to evasion of future vac-
cine induced protection, lessening the herd immunity poten-
tial of vaccination, similar to influenza A vaccines.
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